Publicacións en colaboración con investigadores/as de Universidade da Coruña (72)

2024

  1. Parvimonas micra can translocate from the subgingival sulcus of the human oral cavity to colorectal adenocarcinoma

    Molecular Oncology, Vol. 18, Núm. 5, pp. 1143-1173

  2. The multispecies microbial cluster of Fusobacterium, Parvimonas, Bacteroides and Faecalibacterium as a precision biomarker for colorectal cancer diagnosis

    Molecular Oncology, Vol. 18, Núm. 5, pp. 1093-1122

2021

  1. Signaling pathways in CRC

    Foundations of Colorectal Cancer (Elsevier), pp. 519-528

2020

  1. A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus

    Clinical and Translational Oncology, Vol. 22, Núm. 9, pp. 1565-1579

2017

  1. Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy

    Clinical and Translational Oncology, Vol. 19, Núm. 10, pp. 1175-1182

2015

  1. Circulating miR-200c and miR-141 and outcomes in patients with breast cancer

    BMC Cancer, Vol. 15, Núm. 1

  2. Clinical implications of epithelial cell plasticity in cancer progression

    Cancer Letters, Vol. 366, Núm. 1, pp. 1-10

  3. Radium-223 dichloride: A new paradigm in the treatment of prostate cancer

    Expert Review of Anticancer Therapy, Vol. 15, Núm. 3, pp. 339-348

  4. Side effects of targeted therapy

    Springer New York, pp. 377-416

  5. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors

    Redox Biology, Vol. 6, pp. 421-425

  6. Vías de señalización en cáncer de colon

    Abordaje multidisciplinar de cáncer colorrectal (Andavira), pp. 439-452

2014

  1. Cancer stem cells in genitourinary cancer

    Stem Cells in Cancer: Should We Believe or Not? (Springer Netherlands), pp. 149-165

  2. Circulating levels of GDF15, MMP7 and miR-200c as a poor prognostic signature in gastric cancer

    Future Oncology, Vol. 10, Núm. 7, pp. 1187-1202

  3. MicroARN circulantes en sangre de pacientes con cáncer de próstata

    Actas Urologicas Espanolas, Vol. 38, Núm. 10, pp. 633-639

  4. Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer

    Clinical Cancer Research, Vol. 20, Núm. 7, pp. 1925-1934

  5. Role of the microtubule-targeting drug vinflunine on cell-cell adhesions in bladder epithelial tumour cells

    BMC Cancer, Vol. 14, Núm. 1

  6. Stem cells in cancer: Should we believe or not?

    Springer Netherlands, pp. 1-299

  7. The universal stem cell source: Does it exist?

    Stem Cells in Cancer: Should We Believe or Not? (Springer Netherlands), pp. 1-22

2013

  1. Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

    Clinical and Translational Oncology, Vol. 15, Núm. 6, pp. 425-433

  2. Erratum: Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor (Clinical and Translational Oncology DOI: 10.1007/s12094-012-0985-x)

    Clinical and Translational Oncology